Trials / Unknown
UnknownNCT05831007
Safety and Efficacy Study of LX102-C01 Treatment of Neovascular Age-Related Macular Degeneration (nAMD)
An Open Label Dose Escalation Clinical Trial to Evaluate the Safety and the Efficacy of LX102-C01 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Academic / Other
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety and efficacy of LX102-C01 treatment of nAMD. This study will enroll subjects aged ≥ 50 years old to receive a single unilateral intravitreal (IVT) injection of LX102-C01 to evaluate its safety and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | LX102-C01 Injection | Qualified subjects will receive a single unilateral intravitreal injection of LX102-C01 at Day 0 in the trial. |
Timeline
- Start date
- 2021-12-06
- Primary completion
- 2023-06-01
- Completion
- 2024-06-01
- First posted
- 2023-04-26
- Last updated
- 2023-04-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05831007. Inclusion in this directory is not an endorsement.